ROCKET PHARMACEUTICALS, INC. — Remuneration Information 2022

Apr 29, 2022

DEFA14A 1 ny20002921x3_defa14a.htm FORM DEFA14A Licensed to: Broadridge Finanicial Soultions, Inc. Document created using EDGARfilings PROfile 8.1.1.0 Copyright 1995 - 2022 Broadridge

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☒ Filed by a party other than the Registrant ☐

Check the appropriate box:

☐	​	Preliminary Proxy Statement
☐	​	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐	​	Definitive Proxy Statement
☒	​	Definitive Additional Materials
☐	​	Soliciting Material under §240.14a-12

ROCKET PHARMACEUTICALS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒	​	No fee required
☐	​	Fee paid previously with preliminary materials.
	​	​ ​
☐	​	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.